Peptide drugs offer certain advantages as drugs due to their high biological activity, high specificity and low toxicity. Currently, most peptide drugs are administered by the parental route and approximately 75% are given as injectables. However, alternative administration forms are gaining increasing traction, including oral, intranasal, and transdermal delivery routes. The United States (US) and European Union (EU) are the major markets for drugs of all kinds and, as a consequence, first approvals for peptide therapeutics have occurred primarily in one of these two regions. The near-term prospects for additional approvals are excellent because the pipeline includes more than a dozen molecules in late-stage clinical studies and marketing approval applications. Recent successes in the development of peptides as therapeutics are likely to spur additional growth in this sector.
The global peptide therapeutics market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug category (branded and generic), routes of administration (oral and parenteral), therapeutic application (Acromegaly; Cancer – Zoladex, Velcade, Lupron/ Enantone/ Eligard; Cardiovascular – Angiomax, Integrilin; Central Nervous System – Copaxone; Gastrointestinal Disorders – Gattex, Linzess; Hematological Disorders – Firazyr, Kalbitor; Infection –Incivek, Victrelis; Metabolic Disorders – Victoza, Byetta; and Respiratory Disorders), and also forecasts growth trends (CAGR% – 2017 to 2021).
The global peptide therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global peptide therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global peptide therapeutics market and included in this report are Amgen, Inc., AstraZeneca plc., Bachem Holding AG, CordenPharma International GmbH, Eli Lilly and Company, Ipsen S.A., Lonza Group Ltd., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, PolyPeptide Group, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Ltd., and Teva Pharmaceutical Industries Ltd.